Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,841 to 1,860 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Intervention vs Control: Healthcare Utilization | 920 of 2,353 1,080 of 2,479 | -4.5 points -7.2 to -1.7 | 4,832 | NCT03207776 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD |
| Intervention vs Control: Patient-centric (Protocol Defined) Readmission Rate | 659 of 2,353 753 of 2,479 | -2.4 points -4.9 to 0.2 | 4,832 | NCT03207776 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: serious adverse events | 1,004 of 2,411 1,052 of 2,417 | -1.9 points -4.7 to 0.9 | 4,828 | NCT00553410 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer |
| Arm B (Short Term Storage) vs Standard of Care (Long Term Storage): deaths from any cause | 687 of 2,410 678 of 2,414 | 0.4 points -2.1 to 3.0 | 4,824 | NCT01638416 Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial |
| Rivaroxaban (Xarelto, BAY59-7939) vs Enoxaparin/VKA: serious adverse events | 504 of 2,412 495 of 2,405 | 0.3 points -2.0 to 2.6 | 4,817 | NCT00439777 Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study |
| Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy: deaths from any cause | 205 of 2,400 247 of 2,404 | -1.7 points -3.4 to -0.1 | 4,804 | NCT01358877 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer |
| LCZ696 vs Valsartan: All-cause Mortality | 342 of 2,407 349 of 2,389 | -0.4 points -2.4 to 1.6 | 4,796 | NCT01920711 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction |
| Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Any Coronary Revascularization | 278 of 2,391 288 of 2,395 | -0.4 points -2.2 to 1.4 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Coronary Revascularization | 190 of 2,391 205 of 2,395 | -0.6 points -2.2 to 0.9 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Events | 170 of 2,391 167 of 2,395 | 0.1 points -1.3 to 1.6 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event or Hospitalization for Unstable Angina That Led to Urgent Coronary Revascularization | 201 of 2,391 207 of 2,395 | -0.2 points -1.8 to 1.3 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Major Adverse Cardiovascular Event, Coronary Revascularization, Hospitalization for Congestive Heart Failure or All Cause Mortality | 344 of 2,391 345 of 2,395 | -0.0 points -2.0 to 2.0 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Hospitalization for Congestive Heart Failure | 48 of 2,391 53 of 2,395 | -0.2 points -1.0 to 0.6 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With All-cause Mortality | 96 of 2,391 83 of 2,395 | 0.5 points -0.5 to 1.6 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: deaths from any cause | 96 of 2,391 83 of 2,395 | 0.5 points -0.5 to 1.6 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: Number of Subjects With Hospitalization for Unstable Angina That Led to Unplanned Coronary Revascularization | 41 of 2,391 50 of 2,395 | -0.4 points -1.2 to 0.4 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Methotrexate vs Placebo: serious adverse events | 569 of 2,391 549 of 2,395 | 0.9 points -1.5 to 3.3 | 4,786 | NCT01594333 Cardiovascular Inflammation Reduction Trial |
| Interactive Two-way SMS Dialogue vs No SMS Control: Exclusive Breastfeeding | 2,190 of 2,386 2,217 of 2,396 | -0.7 points -2.3 to 0.8 | 4,782 | NCT04598165 Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support |
| Telmisartan (TRANSCEND) vs Placebo (TRANSCEND): TRANSCEND. New Microalbuminuria | 276 of 2,372 363 of 2,403 | -3.5 points -5.4 to -1.5 | 4,775 | NCT00153101 Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. |
| N-Acetylcysteine (NAC) vs Placebo: Number of Participants With Serious, Adverse, Patient-Centered Events, Including Death, Need for Acute Dialysis, or Persistent Decline in Kidney Function, Comparing Oral N-Acetylcysteine With Oral Placebo. | 115 of 2,391 112 of 2,381 | 0.1 points -1.1 to 1.3 | 4,772 | NCT01467466 Prevention of Serious Adverse Events Following Angiography |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=93
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03207776-ce316c8b",
"title": "Intervention vs Control: Healthcare Utilization",
"summary": "920 of 2353 against 1080 of 2479; risk difference -4.5 points, 95% interval -7.2 to -1.7; NCT03207776, An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD",
"record": "/library/comparisons/NCT03207776-ce316c8b",
"nct_id": "NCT03207776",
"kind": "outcome",
"participants": 4832,
"risk_difference": {
"value": -0.044669314892783196,
"lower": -0.07233647766671894,
"upper": -0.016889691388850114
},
"group_1": "920 of 2,353",
"group_2": "1,080 of 2,479",
"difference": "-4.5 points",
"interval": "-7.2 to -1.7",
"trial_title": "An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD"
},
{
"id": "NCT03207776-cfcd3162",
"title": "Intervention vs Control: Patient-centric (Protocol Defined) Readmission Rate",
"summary": "659 of 2353 against 753 of 2479; risk difference -2.4 points, 95% interval -4.9 to 0.2; NCT03207776, An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD",
"record": "/library/comparisons/NCT03207776-cfcd3162",
"nct_id": "NCT03207776",
"kind": "outcome",
"participants": 4832,
"risk_difference": {
"value": -0.02368351440669414,
"lower": -0.049262433472598496,
"upper": 0.0019739846586620535
},
"group_1": "659 of 2,353",
"group_2": "753 of 2,479",
"difference": "-2.4 points",
"interval": "-4.9 to 0.2",
"trial_title": "An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=94",
"request_id": "Vl1fvgGHf2EcdqGH"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant